A recent JAMA Insights article on nicotine pouches provides a useful overview of the concerns and unanswered questions surrounding a rapidly growing category of smoke-free nicotine products. Published in 2026 by Thomas M. Piasecki, Megan E. Piper and Hasmeena Kathuria, the article examines patterns of nicotine pouch use in the United States, nicotine exposure, potential adverse effects, youth uptake and what is currently known about their health implications.
The article is largely cautionary, and many of the issues it raises deserve serious consideration. Nicotine is addictive, nicotine pouches are not risk-free, and questions remain around oral health, cardiovascular effects, accidental exposure and long-term use. At the same time, the paper also demonstrates how much remains uncertain. This distinction is important for policymakers: identifying potential risks is not the same as establishing that different nicotine products have equivalent risk profiles.
The Concerns Should Be Taken Seriously
The JAMA article highlights several areas of concern associated with nicotine pouch use. These include local oral effects, nicotine dependence and poisoning risks, particularly where products may be accidentally ingested by young children. It also discusses adolescent and young-adult use, noting the importance of monitoring how an expanding market could affect patterns of nicotine initiation.
These concerns should not be dismissed by those advocating risk-proportionate nicotine regulation. Instead, they strengthen the case for appropriate safeguards. Effective age restrictions, responsible marketing, child-resistant packaging, clear labelling, manufacturing and ingredient standards, and enforcement against non-compliant products should form part of any credible regulatory framework.
Long-Term Evidence Remains Limited
One of the most important themes running through the JAMA discussion is uncertainty. The authors note important limitations in the available evidence concerning the long-term consequences of nicotine pouch use, including questions around oral and cardiovascular health.
This uncertainty matters. It means manufacturers, regulators and public-health researchers should avoid making claims that extend beyond the available evidence. It also reinforces the need for longer-term epidemiological research, toxicological assessment, biomarker studies and post-market surveillance.
However, absence of long-term evidence should not automatically be interpreted as evidence that nicotine pouches carry risks equivalent to combustible cigarettes. Uncertainty needs to be communicated as uncertainty rather than converted into assumptions of either safety or equivalent harm.
Comparative Risk Still Matters
A particularly important element of the discussion is the distinction between absolute and comparative risk. A product can carry health risks while still presenting a materially different exposure profile from another product.
Nicotine pouches do not involve combustion or inhalation. The JAMA article acknowledges that adults who completely switch from smoking to nicotine pouches can reduce their exposure to many carcinogens and toxicants associated with cigarette smoking. At the same time, the authors caution that this does not establish nicotine pouches as harmless or determine their long-term health effects.
Both points matter. Public-health discussions should be capable of recognising potential harms from nicotine pouches while also recognising meaningful differences between oral nicotine use and inhaling cigarette smoke.
For regulation, the relevant question should therefore extend beyond whether a product presents any risk. Policymakers also need to consider how its risks compare with those of other nicotine products and how regulatory decisions may affect patterns of use across the population.
Cardiovascular Questions Need Product-Specific Evidence
Cardiovascular health is another area where careful interpretation is particularly important. Nicotine has known physiological effects, including effects on heart rate and blood pressure, so cardiovascular concerns should not be disregarded. But establishing the effects of nicotine itself is different from determining the long-term cardiovascular outcomes associated specifically with modern tobacco-free nicotine pouches.
The JAMA discussion highlights the limited nature of product-specific evidence in this area. This is consistent with broader reviews calling for additional research into the cardiovascular implications of newer oral nicotine products.
The appropriate response is therefore neither to assume safety nor to infer long-term outcomes that have not yet been demonstrated. Better product-specific research is needed to determine how formulation, nicotine strength, frequency and duration of use influence health outcomes.
Smoking Cessation and Switching Are Different Questions
The article also raises an important issue concerning smoking cessation. Nicotine pouches should not automatically be presented as clinically established smoking-cessation medicines. Evidence supporting a therapeutic cessation claim requires appropriate clinical research and regulatory assessment.
However, clinical smoking cessation and consumer switching are not necessarily the same research question. An adult smoker completely replacing cigarettes with a non-combustible nicotine product represents a different outcome from using that product as an approved therapeutic intervention.
Future research should therefore distinguish between complete switching, dual use, temporary experimentation, continued smoking and medically supported cessation. Combining these outcomes can make it harder to understand the actual population-level implications of nicotine pouch availability.
Youth Protection and Adult Risk Reduction Can Coexist
Youth use is understandably one of the most prominent concerns surrounding emerging nicotine products. Nicotine products should not be marketed or sold to children, and regulators should respond where evidence identifies weaknesses in youth protection.
But protecting young people and recognising differences in risk among products used by adults need not be competing objectives.
Age verification, retailer accountability, restrictions on youth-oriented marketing, child-resistant packaging, appropriate product presentation, manufacturing standards and enforcement can all contribute to reducing youth access without requiring every nicotine product to be regulated as though its characteristics and risks were identical to cigarettes.
The challenge is to design regulation that addresses the risks associated with the product itself while also considering the consequences that different regulatory approaches may have for adults who currently smoke.
Industry Has a Responsibility to Strengthen the Evidence
The limitations identified by JAMA also place responsibility on the nicotine sector. If manufacturers argue that nicotine pouches should receive differentiated regulatory treatment, those arguments need to be supported by credible evidence.
That means greater investment in toxicology, pharmacokinetics, oral-health research, cardiovascular research, behavioural studies and long-term surveillance. Research should also account for differences between products, including nicotine strength, ingredients, formulation and patterns of use.
Greater transparency around research and product standards can help regulators distinguish between evidence-based claims and commercial assertions. As the market develops, the scientific evidence supporting it needs to develop as well.
Regulation Should Reflect Both Evidence and Uncertainty
The JAMA article is valuable precisely because it presents many of the criticisms that the nicotine pouch sector needs to address. Concerns about addiction, youth use, oral effects, accidental exposure and unanswered long-term health questions should not simply be dismissed because pouches do not involve combustion.
At the same time, those concerns should not eliminate consideration of comparative risk. Nicotine pouches are not risk-free, and important evidence gaps remain, but their exposure pathway differs substantially from cigarette smoking.
A proportionate regulatory framework should therefore be capable of holding both realities at once. It should protect children and non-users, establish appropriate standards, restrict irresponsible marketing, support surveillance and encourage stronger research, while remaining responsive to emerging evidence about differences between nicotine products.
The objective should not be to predetermine that nicotine pouches are either harmless or equivalent to cigarettes. It should be to build an evidence base strong enough to understand where they sit within the wider nicotine landscape and to adapt regulation accordingly.
For GINN, this is ultimately the broader lesson from the JAMA review: uncertainty is a reason to generate better evidence, not a reason to stop distinguishing between products.
Source
Piasecki TM, Piper ME, Kathuria H. Nicotine Pouches. JAMA. 2026.
